Acute myeloid leukemia (AML) is more prevalent in older adults, with an incidence in the
United States of 17.6 per 100,000 for those⩾ 65 years of age, compared with an incidence of …

Acute Myeloid Leukemia (AML) is a disorder affecting primarily elderly individuals and
poses significant treatment challenges. Much has been learned about the underlying …

With a median age at diagnosis of approximately 65–70 years, acute myeloid leukemia
(AML) represents a major therapeutic challenge in the elderly. Only 30–35% of elderly …

Simple Summary In this review article, we describe the landscape of available treatments for
older and medically unfit patients with AML. We review the historical practice of AML …

Introduction Acute myeloid leukemia (AML) is an aggressive disease predominantly
affecting the elderly population. The elderly population represents a challenging group to …

Acute myeloid leukemia (AML) is a disease of older adults, with a median age of 67 years at
presentation. In the past, only a third of older patients (defined as individuals older than 60 …

The treatment of acute myeloid leukemia has been associated with dismal outcomes despite
available therapies. The morbidity and mortality associated with acute myeloid leukemia …

Opinion statement The treatment of acute myeloid leukemia (AML) has evolved considerably
over the past several years. Advances in the field have historically benefited younger …

With a few subgroups as exceptions, such as younger patients with more favorable genetic
disease, improvement in the treatment of acute myeloid leukemia has been slow. There is a …

Acute myeloid leukemia (AML) is predominantly a disease of older adults, with a median
age at diagnosis of over 65 years. AML in older adults differs biologically and clinically from …